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Phenotypic and genotypic detection of metallo-beta-lactamases 
in Carbapenem resistant Acinetobacter baumannii 
 
Abstract 
Background: Carbapenem resistance in Acinetobacter baumannii has become a major 
concern for treating physicians. The aim of this study was to investigate the prevalence of 
metallo β-lactamase (MBL) genes (bla VIM , and blaIMP) among isolated multidrug-resistant 
A. baumannii . 
Methods: Fifty non-repetitive carbapenem-resistant A. baumannii isolates were collected. 
Antibiotic susceptibility was performed by disk diffusion method. MICs were determined 
by E test method. The resistant strains were tested for the production of carbapenemases 
by the Modified Hodge Test (MHT) followed by EDTA-disk synergy test was performed 
for metallo-β-lactamases (MBL) phenotypic detection. Detection of bla VIM , and blaIMP 
was performed by PCR followed by sequencing. 
Results: All isolates had a multidrug resistant profile, and were all resistant to all 
antibiotics including the carbapenems but remained susceptible to colistin. Among these 
isolates, Carbapenemase production was confirmed by the Modified Hodge test for 42 
(84%) isolates. Phenotypic method showed the production of MBL in 15 (30%) isolates. 
PCR techniques revealed that out of 50 isolates, 13 (26%) were positive for blaVIM and all 
were negative for blaIMP. 
Conclusion: Our study concludes that the high prevalence of carbapenem resistant 
Acinetobacter species with MBL production is one of the main concerns in our country 
and this situation needs strict infection control measures. 
Keywords: Acinetobacter baumannii, Carbapenem resistance, Metallo-beta-lactamases, 
Modified hodge test 
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TAcinetobacter baumannii is a gram-negative coccobacillus initially considered to 
be an opportunistic pathogen, which plays a vital role as a major cause of healthcare-
associated infections (1, 2). In recent years, Acinetobacter has become resistant to most 
effective antimicrobial agents and causing a high incidence rate of morbidity and mortality 
especially in the intensive care unit in many countries (3, 4). The emergence of multidrug-
resistant (MDR: resistant to at least one agent in three or more antimicrobial categories or 
to one key treatment antibiotic), extensively drug-resistant(XDR: resistant to at least one 
agent in all but two or fewer antimicrobial categories) or pandrug-resistant (PDR: resistant 
to all agents in all antimicrobial categories) isolates causes serious problems in treating 
Acinetobacter infections (4, 5). Carbapenems are considered the most effective drugs for 
the treatment of infections caused by multidrug- resistant gram negative bacteria, when 
these bacteria are resistant to other β-lactam antibiotics.(6). Unfortunately, many studies 
have reported high carbapenem resistance rates among these pathogens from different 
countries and this situation expresses serious therapeutic challenges (7, 8). 
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The ability to produce Carbapenemase enzymes such as 
oxacillinases (Ambler class D OXA-type) and metallo-β-
lactamases (MBLs) (Ambler class B) are the most frequent 
resistance mechanisms in A. baumannii (9, 10). Since 
resistance to carbapenems is difficult to detect by routine 
disc diffusion method (11), various inhibitin-based tests such 
as the double-disk synergy test, combined disk test and  the 
modified Hodge test (MHT) have been recommended by 
CLSI as general phenotypic methods for detection of 
carbapenemases (12, 13). Also, polymerase chain reaction 
(PCR) is used as a reliable method for the identification of 
the most prevalent genes in carbapenemase positive clinical 
isolates (14). This study aimed to detect the frequency of 
carbapenemase and MBL producing MDR   A. baumannii by 
phenotypic methods and the detection of the blaVIM and 
blaIMP genes by (PCR) in patients of hospitals affiliated with 
Babol University of Medical Sciences. 
 
 
Methods 
Fifty non-duplicate carbapenem resistant Acinetobacter 
isolates were collected from several units of Babol 
University of Medical Sciences affiliated hospitals, Babol, 
Iran, from January 2015 to June 2016. The most common 
sources of strains were isolated from respiratory samples 
(endotracheal aspirates, sputum), ulcers, urinary specimens 
and blood. Samples were cultured on bacteriological blood 
agar and eosin methylene blue (EMB) media (Merck, 
Germany) and incubated in aerobic condition at 37ºC for 24 
hours. The colonies were identified up to the species by 
specific biochemical tests using API 20E strips (bioMérieux, 
Marcy l’Etoile, France) according to the manufacturer's 
instructions. Strains were stored at -80°C for molecular 
analysis. 
Antimicrobial Susceptibility Testing and determination 
of MIC: The sensitivity of different classes of antimicrobial 
agents was determined using disk diffusion method 
according to CLSI guidelines (2015). The following 
antibiotics were used; cefazidime (CAZ :30 µg), colsitin 
(Col:110 µg), cefepime (FEP: 30 µg), imipenem (Imp :30 
µg), meropenem (MER: 30 µg), ciprofloxacin (CIP: 5 µg), 
ceftriaxone (CRO:30 µg), piperacillin-tazobactam (PTZ: 
100/10 µg), trimethoprim-sulfamethoxazole (SXT 
:1.25/23.75 µg) ,Gentamycin (GM: 10 µg), ampicillin/ 
sulbactam (SAM: 10/10 µg) and ertapenem (ETP: 10 μg) 
(MAST, UK). Escherichia coli ATCC25922 and 
Pseudomonas aeruginosa ATCC 27853 strains were used as 
negative control strains. MBL-producing P. aeruginosa and 
carbapenemase-producing A. baumannii were used as 
positive control strains. In addition, Minimum Inhibitory 
Concentrations (MICs) were determined by E-test MIC 
strips (BD, France, and Liofilchem R) .The concentration 
ranges for the E-test was 0.002–32 µg/ ml for the 
carbapenems (BD,France, and Liofilchem R ). 
Screening for the Carbapenemase Production: All 
isolates with reduced susceptibility to meropenem and 
imipenem (diameter of zones of inhibition ≤13mm) by disc 
diffusion method were tested for the presence of 
carbapenemase by Modified Hodge test (MHT) using a 
meropenem disc (10 μg) as per CLSI guidelines. The quality 
strain used is E. coli ATCC 25922. Also, the double disk 
synergy test (DDST) for the ability of the detection of MBL 
possessing isolates (15), and compared to PCR for the 
detection of MBL gene blaIMP and blaVIM. 
DNA extraction and amplification of carbapenemas 
genes: DNA was extracted using a kit supplied by Roche, 
(Roche Diagnostics,Germany). PCR amplification for the 
detection of blaVIM and blaIMP genes were carried out on a 
thermal cycler (Eppendorf, Hamburg, Germany). The 
sequences of used primers for the amplification of the blaVIM 
gene were F:5'-AGTGGTGAGTATCCGACAG-3' and R:5'-
TGAAAGTGCGTGGAGAC-3' which produce a 261bp 
PCR product. The sequences of primers used for amplification of 
blaIMP gene were F:5'-TCGTTTGAAGAAGTTAACGG-3' 
and R:5'-ATGTAAGTTTCAAGAGTGATGC-3' which are 
known to give a PCR product of about 568bp. The PCR 
reaction was performed in 50 μL volumes that contained 10  
µL extractions of DNA (equal to 1 μg), 5 pmol/L  from each 
primer, 1.5  mmol/L MgCl2, 0.2 mmol/L dNTPs (Fermentas, 
GmbH, Germany) and 1.5 unit of Taq DNA polymerase 
enzyme. PCRs were run using the following steps: primary 
denaturation at 94 ºC for 5 minutes followed by 30 cycles of 
denaturation at 94 ºC for 25 seconds, annealing at 52 ºC for 
40 seconds and extending at 72 ºC for 50 seconds. Moreover 
one cycle for the final extension at 72 ºC for six minutes was 
performed. Then, 10μL of the PCR products was conducted 
in 1.5% agarose gel (Cinagene Co, Iran) stained by 0.5µg of 
ethidium bromide/ml (Sigma,  Germany) and the results 
were evaluated in the presence of 100 bp. DNA size marker 
(Fermentas Co, Ukraine), visualized under UV trans 
illuminator. Finally, amplification products were sequenced 
by Macrogen Inc, Seoul, Korea. The collected data were 
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statistically analyzed using SPSS program (software Version 
17.0). 
 
 
Results 
From 50 carbapenem-resistant A. baumannii isolates, 30 
(60%) were collected from female patients. The mean age of 
patients was 65.25 years and 44 (88%) were aged 50 years 
and older. The highest number of these isolates were found 
in patients hospitalized in intensive care units (ICUs) 34 
(68%), followed by infectious disease units 12(24%) and 
surgical clinics 4 (8%). The most common sources of these 
strains were isolated from respiratory samples (endotracheal 
aspirates, sputum) 30 (60%), ulcers 12 (24%), urinary 
specimens 6 (12%) and blood 2 (4%), respectively. It should 
be noted that 46 (92%) of patients recovered and were 
eventually discharged with good general condition and 4 
(8%) patients passed away.All isolates had a multidrug 
resistant profile, and were all resistant to all antibiotics 
including the carbapenems. The carbapenem resistance 
profile of all isolates was confirmed by determining the MIC 
value of meropenem by the E-test method. The only class of 
antibiotics to which the isolates were susceptible was colistin 
sulfate (94%) and trimethoprim-sulfamethoxazole (14%). 
The results of the antimicrobial susceptibility testing showed 
that colistin was the most effective in vitro antimicrobials 
against the majority of A. baumannii isolates. Only three 
isolates were resistant to colistin. Moreover for meropenem 
and imipenem, the result of the E-test was consistent with 
the disk diffusion method and 100% of isolates were 
resistant by the two methods. Among these isolates, 
carbapenemase production was confirmed by the modified 
Hodge test for 42 (84%) isolates (figure 1).  
 
 
 
 
 
 
 
 
 
 
Figure 1. Phenotypic detection of metallo-beta-
lactamases by combined disk test and double disk 
synergy test. 
The phenotypic method showed the production of MBLs 
in 15 (30%) isolates (figure 2). Searching for MBLs genes in 
all isolates by PCR technique revealed that out of 50 isolates, 
13 (26%) were positive for blaVIM and all of them were 
negative for blaIMP (figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The MHT on a 100 mm MH plate strain 
positive result. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Agarose gel electrophoresis of PCR amplified 
productsof Acinetobacter baumannii blaVIM MBLs 
gene: Lane 1 -3, 4: positive isolate, Lane M: DNA size 
marker, Lane C+ : positive control, Lane C-: negative 
control. 
 
Discussion 
In the present study, A. baumannii were isolated most 
commonly from respiratory tract specimens, followed by 
wounds and urine. Many studies also reported that 
respiratory secretion specimens are the major source of A. 
baumannii isolates, followed by wounds (6, 16). In the past 
decad,e many reports have indicated that the frequency of 
MDR  A. baumannii has to increase from 50% in 2001–2007 
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to 74% in 2010–2015 among the hospitalized patients in Iran 
(17, 18). The prevalence rate of A. baumannii isolates from 
other neighboring countries, including Turkey , Pakistan, 
Emirates and Saudi Arabia are similar to the antimicrobial 
profile reported in Iran (19, 20). Carbapenems are generally 
used as the last choice in the treatment of MDR gram-
negative bacterial infections (21). In accordance with 
previously performed studies, antibiotic susceptibility and 
MIC tests in the current work showed that 94% of 
A.baumannii isolates were found to be PDR, which indicate 
resistance to all classes of antibiotics except colistin. 
However, some studies have reported that A. baumannii 
isolates are becoming resistant to colistin (22, 23). In our 
study, we found high frequency resistance to imipenem and 
meropenem, which correlates with previously reported 
studies (24). In view of the increasing resistance to 
carbapenems, this study also highlights phenotypic tests such 
as the modified Hodge test for a first-line detection of 
carbapenemase-producing isolates (25, 26). Results from the 
MHT in the current study showed that 84% of A.baumannii 
isolates were carbapenemase producers. These results are 
supported by several studies which have found that the MHT 
is a useful screening test for Carbapenemase production (27, 
28). According to the findings of several studies, the use of 
DDST is one of the more reliable methods for the detection 
of Ambler class B MBL production with a high rate of 
positivity (29).  
Furthermore, our study has shown the lowest positivity 
rate (30%) by DDST method and our result are similar to a 
study conducted by Shivaprasad et al (30). The results of the 
present work show that the phenotypic and genotypic results 
of the detection of MBL producing isolates were similar, and 
that the PCR assay of all carbapenem resistant isolates 
revealed that 26% (13/50) of isolates carried the blaVIM gene. 
In the current study, the blaIMP gene was not detected among 
the A. baumannii isolates. In a previous study conducted by 
Fallah et al., results showed that the prevalence of the blaVIM  
and blaIMP  gene in A. baumannii were 17%  and 4%, 
respectively(31). In a study conducted by Erfani et a,l. 
results showed that the prevalence of the blaVIM  gene in A. 
baumannii is 60.4% while no blaIMP positive cases were 
reported (32). In another study from Iran in 2018, the 
prevalence of blaVIM and blaIMP genes was found to be 62.3 
and 30.4 %, respectively (33). 
In conclusion this study confirmed the high prevalence of 
multidrug-resistant A. baumannii isolates in the ICU, which 
is emerging as a predominant pathogen in hospitals. In case 
of multidrug-resistant Acinetobacter infections, colistin is 
the best choice of antibiotic available for the effective 
treatment of serious infections. Initial screening of the 
putative carbapenemase producers will help to manage 
infection-control policy and early directed therapy. Easy 
detection methods are required for routine clinical labs. Our 
study showed that MHT and E-test were equally efficient to 
detect MBL production, followed by combined disc test. The 
use of molecular methods is essential, especially in limiting 
the spread of infection. 
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